top
Search terms
Results 1 - 5 of 5 - ordered by :
Epeuropace

Phase I, baseline cohort before the introduction of non-VKA oral anticoagulants (NOACs); Phase II, just after the introduction of the first NOAC dabigatran, with 2-year follow-up in ...

Europace, CLINICAL RESEARCH, Menno V. Huisman, Chang Sheng Ma, Hans-Christoph Diener, Sergio J. Dubner, Jonathan L. Halperin, Kenneth J. Rothman, Christine Teutsch, Nils Schoof, Eva Kleine, Dorothee ...

Date : 01/09/2016 Item size : 261631 bytes
Epeuropace

Over time many stroke risk stratification schema have been developed, initially with the objective to better define high-risk patients who could be subjected to an inconvenient (and potentially ...

Europace, Editorial, Ron Pisters, Jonas B. Olesen, Gregory Y.H. Lip

Date : 01/01/2012 Item size : 140103 bytes
Ehjournal

Abstract Background The EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot) provides systematic collection of contemporary data regarding the ...

European Heart Journal, Fast Track ESC Clinical Trial and Registry Update, Gregory Y.H. Lip, Cécile Laroche, Popescu Mircea Ioachim, Lars Hvilsted Rasmussen, Laura Vitali-Serdoz, Lucian Petrescu, ...

Date : 14/12/2014
Epeuropace

Abstract This EP Wire surveyed clinical practice with regard to the use of antithrombotic therapy in relation to device implantation (pacemakers, ICT, resynchronization therapy) and atrial ...

Europace, EP WIRE, Gregory Y.H. Lip, Alessandro Proclemer, Nikolaus Dagres, Maria Grazia Bongiorni, Thorsten Lewalter, Carina Blomstrom-Lundqvist

Date : 01/05/2012
Epeuropace

Randomized trials in patients with atrial fibrillation (AF) have consistently demonstrated that compared with placebo, adjusted-dose vitamin K antagonists (VKAs) reduce the incidence of stroke by ...

Europace, Editorial, Laurent Fauchier, Gregory Y.H. Lip

Date : 01/06/2010